Quarterly ResultAug 6, 2026, 05:41 PM
Ernexa Q2 Net Loss $4.0M; Goodwill Impairment $2.0M
AI Summary
Ernexa Therapeutics Inc. reported a net loss of $4.0 million for the three months ended June 30, 2026, and $9.5 million for the six months, which included a $2.0 million goodwill impairment charge. The company ended the period with $5.0 million in cash and an accumulated deficit of $255.2 million. Management noted a going concern risk but expects to cover shortfalls through its At-the-Market (ATM) program, having raised $3.7 million post-quarter end.
Key Highlights
- Net loss for Q2 2026 was $4.0 million.
- Net loss for H1 2026 was $9.5 million.
- Goodwill impairment charge of $2.0 million recognized in H1 2026.
- Cash balance stood at $5.0 million as of June 30, 2026.
- Accumulated deficit reached $255.2 million.
- Net cash used in operating activities was $6.4 million in H1 2026.
- Received $9.5 million net proceeds from a public offering in February 2026.
- Sold an additional $3.7 million in shares via ATM post-June 30, 2026.
Price Impact
More from ERNA